LINC00324 in cancer: Regulatory and therapeutic implications

Qing Xia; Jinze Shen; Qurui Wang; Yufei Ke; Qibin Yan; Hanbing Li; Dayong Zhang; Shiwei Duan

doi:10.3389/fonc.2022.1039366

LINC00324 in cancer: Regulatory and therapeutic implications

Front Oncol. 2022 Dec 22:12:1039366. doi: 10.3389/fonc.2022.1039366. eCollection 2022.

Authors

Qing Xia^{1

2

3}, Jinze Shen¹, Qurui Wang¹, Yufei Ke¹, Qibin Yan¹, Hanbing Li², Dayong Zhang¹, Shiwei Duan¹

Affiliations

¹ Department of Clinical Medicine, Zhejiang University City College School of Medicine, Hangzhou, Zhejiang, China.
² College of Pharmacy, Zhejiang University of Technology, Hangzhou, Zhejiang, China.
³ Key Laboratory of Novel Targets and Drug Study for Neural Repair of Zhejiang Province, School of Medicine, Zhejiang University City College, Hangzhou, Zhejiang, China.

Abstract

LINC00324 is a 2082 bp intergenic noncoding RNA. Aberrant expression of LINC00324 was associated with the risk of 11 tumors and was closely associated with clinicopathological features and prognostic levels of 7 tumors. LINC00324 can sponge multiple miRNAs to form complex ceRNA networks, and can also recruit transcription factors and bind RNA-binding protein HuR, thereby regulating the expression of a number of downstream protein-coding genes. LINC00324 is involved in 4 signaling pathways, including the PI3K/AKT signaling pathway, cell cycle regulatory pathway, Notch signaling pathway, and Jak/STAT3 signaling pathway. High expression of LINC00324 was associated with larger tumors, a higher degree of metastasis, a higher TNM stage and clinical stage, and shorter OS. Currently, four downstream genes in the LINC00324 network have targeted drugs. In this review, we summarize the molecular mechanisms and clinical value of LINC00324 in tumors and discuss future directions and challenges for LINC00324 research.

Keywords: LINC00324; RNA-Binding Protein; cancer; ceRNA; prognosis; signaling pathway.

Publication types

Review